drugset / Trial / NCT00006092

Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia

NCT00006092

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have recurrent or refractory acute lymphoblastic leukemia or chronic myelogenous leukemia.

Timeline

Start
2000-08
Primary completion
2003-03
Completion
2003-03

Drugs

EvaluationDrugModalityDoseRoute
Subject arsenic trioxide Small molecule Intravenous

Indications